Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05890599
Other study ID # S00766-RBK
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 10, 2023
Est. completion date November 2024

Study information

Verified date January 2023
Source University Hospital Tuebingen
Contact Holger Cramer, Professor
Phone +49 711 8101 7858
Email yasemin.anguelov@bosch-health-campus.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluation of the short- and medium-term effect of a yoga intervention in addition to routine care compared to health education in addition to routine care on fatigue in patients with post covid syndrome.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date November 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Confirmed COVID-19 diagnosis - Follow-up symptoms of = 12 weeks - Persistent fatigue (scores =4 on the binomial Chalder Fatigue Scale). - Self-assessment that fatigue was a consequence of COVID-19 disease - Age 18-65 years Exclusion Criteria: - Chronic medical conditions or regular use of medications associated with fatigue - Indication of health cause of fatigue other than post-COVID. - Indication of other factors as the main cause of fatigue - Physical limitations that do not allow participation in the yoga intervention - Pregnancy, breastfeeding - Concurrent participation in other clinical trials - Current yoga practice

Study Design


Intervention

Behavioral:
Yoga Therapy
The range of interventions is based on previous studies on yoga interventions specifically for fatigue patients as well as on recommendations, for example, from the WHO. The yoga therapy includes 3 elements: yoga postures (asanas), breathing techniques (pranayama) and relaxation moments. Emphasis on postures and breathing techniques that are considered to be effective for fatigue symptoms, as well as specific breathing exercises to strengthen the respiratory muscles and increase lung volume.
Health Education
Health education courses are conducted on-site once a week for 90 minutes over 12 weeks by a psychologist with clinical experience. The courses are didactic in nature and consist of lectures on topics of interest to patients with post-COVID syndrome and fatigue, followed by questions and discussion sessions. Topics include information on post-COVID syndrome and fatigue, an introduction to self-help for post-viral symptoms, psychosocial problems and fatigue, relaxation and stress management, nutrition, sleep hygiene, exercise, respecting one's own limits, acceptance, finding meaning, and achieving goals.

Locations

Country Name City State
Germany Bosch-Health-Campus Stuttgart

Sponsors (3)

Lead Sponsor Collaborator
University Hospital Tuebingen Charite University, Berlin, Germany, Robert Bosch Gesellschaft für Medizinische Forschung mbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Therapy rationale and therapy expectancy The Credibility Expectancy Questionnaire (CEQ) published by Ametrano, et al. 2011 and validated as German version by Rieke, et al. 2013 is used to measure Therapierationale and Therapieerwartung at baseline. It measures these over 6 items using 9-point Likert scales. Week 1
Other Personality dimensions Big-Five-Inventory-10 (BFI-10) is used to assess personality dimensions based on the big-5 model. Week 1
Primary Fatigue The chalder fatigue scale is used to assess the severity of fatigue within the last 4 weeks. It contains 11 questions in a four-step answer format (0-4), 7 of which refer to the degree of physical fatigue and 4 to the degree of mental fatigue. In its binomial evaluation (range 0-11) it can be used with a cut-off of (= 4) to divide patients into those with and those without fatigue. 12 weeks
Secondary Fatigue Chalder Fatigue Scale 24 weeks
Secondary Health related quality of life SF-12 Short Form 12 Health Survey Questionnaire, The SF-12 represents the most commonly used instrument in clinical trials to assess generic quality of life. The questionnaire captures 8 different subscales, which are combined into a physical and a psychological summated scale. 12 weeks
Secondary Health related quality of life SF-12 Short Form 12 Health Survey Questionnaire, The SF-12 represents the most commonly used instrument in clinical trials to assess generic quality of life. The questionnaire captures 8 different subscales, which are combined into a physical and a psychological summated scale. 24 weeks
Secondary Health related quality of life EQ-5D-5L The EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In this study, the EQ-5D-5L is used for cost-effectiveness analysis, together with healthcare-related costs. 12 weeks
Secondary Health related quality of life EQ-5D-5L The EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In this study, the EQ-5D-5L is used for cost-effectiveness analysis, together with healthcare-related costs. 24 weeks
Secondary Psychological symptoms The Hospital Anxiety and Depression Scale asks 14 questions, of which 7 are about anxiety and 7 about depression in patients with physical illnesses and physical complaints. More precisely, it measures the self-assessed severity of patients' anxious and depressive symptoms in relation to the past week. 12 weeks
Secondary Psychological symptoms The Hospital Anxiety and Depression Scale asks 14 questions, of which 7 are about anxiety and 7 about depression in patients with physical illnesses and physical complaints. More precisely, it measures the self-assessed severity of patients' anxious and depressive symptoms in relation to the past week. 24 weeks
Secondary Sleep quality The Pittsburgh Sleep Quality Index (PSQI) assesses the quality of sleep over the past 4 weeks using 24 questions, 17 for self-assessment and 7 for external assessment. It is used clinically to monitor patients with sleep disorders and to screen for sleep disorders in epidemiological studies. 12 weeks
Secondary Sleep quality The Pittsburgh Sleep Quality Index (PSQI) assesses the quality of sleep over the past 4 weeks using 24 questions, 17 for self-assessment and 7 for external assessment. It is used clinically to monitor patients with sleep disorders and to screen for sleep disorders in epidemiological studies. 24 weeks
Secondary Stress The current stress perception of the patients is assessed by means of the Perceived Stress Scale (PSS-10). This measures the current subjective perceived stress of the patients on the basis of 10 items. 12 weeks
Secondary Stress The current stress perception of the patients is assessed by means of the Perceived Stress Scale (PSS-10). This measures the current subjective perceived stress of the patients on the basis of 10 items. 24 weeks
Secondary Post-exertional malaise Post-exertional malaise (PEM) is a delayed worsening of symptoms that occurs after minimal physical or mental activity. The DePaul-Symptom Questionaire (DSQ) is used to asses PEM. 12 weeks
Secondary Post-exertional malaise Post-exertional malaise (PEM) is a delayed worsening of symptoms that occurs after minimal physical or mental activity. The DePaul-Symptom Questionaire (DSQ) is used to asses PEM. 24 weeks
Secondary Body awareness The BAQ is an 18-item scale designed to assess self-reported attentiveness to normal nonemotive body processes, specifically, sensitivity to body cycles and rhythms, ability to detect small changes in normal functioning, and ability to anticipate bodily reactions. Body awareness will be used in mediation analyses of treatment effects. 12 weeks
Secondary Body awareness The BAQ is an 18-item scale designed to assess self-reported attentiveness to normal nonemotive body processes, specifically, sensitivity to body cycles and rhythms, ability to detect small changes in normal functioning, and ability to anticipate bodily reactions. Body awareness will be used in mediation analyses of treatment effects. 24 weeks
Secondary Self-Efficacy The Arthritis Self-Efficacy Scale (ASES) was originally developed in 1989 as part of the Stanford Arthritis Self-Management Study to assess self-efficacy in arthritis patients and has since been used to assess it in many disease conditions. A short version (ASES-8/ASES-D) has been validated. This version surveys in scale level 1-10 the perceived ability to deal with occurring symptoms such as: Pain or fatigue. Self-efficacy will be used in mediation analyses of treatment effects. 12 weeks
Secondary Self-Efficacy The Arthritis Self-Efficacy Scale (ASES) was originally developed in 1989 as part of the Stanford Arthritis Self-Management Study to assess self-efficacy in arthritis patients and has since been used to assess it in many disease conditions. A short version (ASES-8/ASES-D) has been validated. This version surveys in scale level 1-10 the perceived ability to deal with occurring symptoms such as: Pain or fatigue. Self-efficacy will be used in mediation analyses of treatment effects. 24 weeks
Secondary Adverse events Adverse events and serious adverse events are documented. Adverse events include any adverse symptoms, illnesses, disorders, or accidents that occur during the course of the study. Serious adverse events include events occurring during the course of the study that are immediately life-threatening and/or result in serious health problems (specifically, requiring unanticipated hospitalization or prolongation of hospitalization, or resulting in serious disability or incapacitation). The severity as well as the possible causal relationship with the intervention will be assessed by the study physician. 12 weeks
Secondary Adverse events Adverse events and serious adverse events are documented. Adverse events include any adverse symptoms, illnesses, disorders, or accidents that occur during the course of the study. Serious adverse events include events occurring during the course of the study that are immediately life-threatening and/or result in serious health problems (specifically, requiring unanticipated hospitalization or prolongation of hospitalization, or resulting in serious disability or incapacitation). The severity as well as the possible causal relationship with the intervention will be assessed by the study physician. 24 weeks
Secondary C-reactive proteine CRP as marker of pro-inflammatory cytokine activity, from blood samples. 12 weeks
Secondary C-reactive proteine CRP as marker of pro-inflammatory cytokine activity, from blood samples. 24 weeks
Secondary Interleukine-6 IL-6, as marker of pro-inflammatory cytokine activity, from blood samples. 12 weeks
Secondary Interleukine-6 IL-6, as marker of pro-inflammatory cytokine activity, from blood samples. 24 weeks
Secondary D-dimer D-dimer, as a by-product of the blood clotting and break-down process that can be measured via analysis of a blood sample 12 weeks
Secondary D-dimer D-dimer, as a by-product of the blood clotting and break-down process that can be measured via analysis of a blood sample 24 weeks
Secondary Lactate dehydrogenase Lactate dehydrogenase (LDH), measuring the amount of LDH in the blood. Lactate dehydrogenase is an enzyme that the body uses during the process of turning sugar into energy for your cells to use. 12 weeks
Secondary Lactate dehydrogenase Lactate dehydrogenase (LDH), measuring the amount of LDH in the blood. Lactate dehydrogenase is an enzyme that the body uses during the process of turning sugar into energy for your cells to use. 24 weeks
Secondary Leukocytes and lymphocytes Leukocytes and lymphocytes, from blood samples. 12 weeks
Secondary Leukocytes and lymphocytes Leukocytes and lymphocytes, from blood samples. 24 weeks
Secondary Grip strength Repeated measurement of hand strength can help detect physical decline and inflammatory processes Hand strength measurement can be an invaluable tool for monitoring physical performance decline. 12 weeks
Secondary Grip strength Repeated measurement of hand strength can help detect physical decline and inflammatory processes Hand strength measurement can be an invaluable tool for monitoring physical performance decline. 24 weeks
Secondary Movement tracking General tracking of patients' movement habits via activity monitor 12 weeks
Secondary Movement tracking General tracking of patients' movement habits via activity monitor 24 weeks
Secondary Heart rate variability HRV is simply a measure of the variation in time between each heartbeat. This variation is controlled by a primitive part of the nervous system called the autonomic nervous system (ANS). It works behind the scenes, automatically regulating our heart rate, blood pressure, breathing, and digestion among other key tasks. 12 weeks
Secondary Heart rate variability HRV is simply a measure of the variation in time between each heartbeat. This variation is controlled by a primitive part of the nervous system called the autonomic nervous system (ANS). It works behind the scenes, automatically regulating our heart rate, blood pressure, breathing, and digestion among other key tasks. 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06073002 - Effects of a Home-Based Exercise Intervention in Subjects With Long COVID N/A
Completed NCT05047952 - Vortioxetine for Post-COVID-19 Condition Phase 2
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting NCT06091384 - Inspiratory Muscle Strength Training in Post-Covid Syndrome N/A
Not yet recruiting NCT06267300 - Treatment of Post-COVID-19 With Hyperbaric Oxygen Therapy: a Randomized, Controlled Trial Phase 3
Recruiting NCT05986422 - Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS) Phase 2
Not yet recruiting NCT05534997 - Rehabilitation Therapy for Post COVID 19 Chronic Fatigue Syndrome N/A
Recruiting NCT05638633 - Prednisolone and Vitamin B1/6/12 in Patients With Post-Covid-Syndrome Phase 3
Active, not recruiting NCT05630040 - VNS for Long-COVID-19 N/A
Recruiting NCT05841498 - Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome N/A
Enrolling by invitation NCT05981872 - EFFECT OF COGNITIVE BEHAVIORAL THERAPY ON DEPRESSION AND QUALITY OF LIFE IN PATIENTS WITH POST COVID-19 N/A
Active, not recruiting NCT05543408 - Long COVID-19 Syndrome in Primary Care: A Novel Protocol of Exercise Intervention "CON-VIDA Clinical Trial" N/A
Recruiting NCT05817032 - Effect of Telerehabilitation Practice in Long COVID-19 Patients N/A
Recruiting NCT05823896 - imPROving Quality of LIFe In the Long COVID Patient Phase 2
Completed NCT05764070 - Impact of Vagus Nerve Stimulation on Post-Aerobic Activity Recovery in Post SARS-CoV-2 Patients N/A
Completed NCT05765591 - Balneotherapy for Patients With Post-acute Coronavirus Disease (COVID) Syndrome N/A
Recruiting NCT05918965 - Vagus Stimulation in Female Long COVID Patients. N/A
Not yet recruiting NCT06231238 - Balance Acceptance and Commitment Therapy for Long COVID Phase 2
Completed NCT06282627 - The COVID HOME Study: Prospective Cohort Study of Non-hospitalised COVID-19 Patients
Completed NCT05648734 - Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis